News
8h
TipRanks on MSNConvertible Senior Notes: A Barrier to Takeovers at Solaris Energy Infrastructure?Solaris Energy Infrastructure, Inc. (SEI) has disclosed a new risk, in the Debt & Financing category. The provisions within the Convertible Senior ...
Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted ...
17h
TipRanks on MSNCelcuity Completes $201.25 Million Convertible Notes IssuanceCelcuity ( ($CELC) ) has issued an announcement. On July 30, 2025, Celcuity Inc. entered into an underwriting agreement with several underwriters ...
MARA holds 50,000 BTC ($5.9 billion) on its balance sheet, according to data tracked by Bitcoin Treasuries. This makes it the ...
MARA Holdings, a digital energy and infrastructure company, announced the closing of its upsized $950M offering of 0.00% ...
ZTO Express (Cayman) Inc. (NYSE: ZTO and SEHK: 2057) ("ZTO" or the "Company") is a leading and fast-growing express delivery company in China. ZTO provides express delivery service as well as other ...
Quiver AI Summary Nutanix, Inc. has announced the pricing of a $750 million private placement of 0.50% convertible senior notes due 2029, aimed at qualified institutional buyers.
--B2Gold Corp. announces that it is offering convertible senior unsecured notes due 2030 in an aggregate principal amount of US $350 million. The interest rate and the initial conversion rate of ...
FORT WORTH, Texas-- (BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL) (“Omnicell”) today announced the pricing of $150.0 million aggregate principal amount of 1.00% Convertible Senior Notes due ...
Convertible senior notes are used by companies like MicroStrategy. These are debt securities that investors can convert into shares of the issuing company’s stock.
Bentley also granted the initial purchasers of the Notes an option to purchase up to an additional $75.0 million aggregate principal amount of Notes during a 13-day period beginning on, and ...
Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results